港股異動丨雷蛇(1337.HK)放量大漲逾14% 料全年將扭虧為盈
格隆匯11月9日丨雷蛇(1337.HK)漲14.29%,報2.64元創近2年半新高,成交額放大至2.5億港元,總市值234.5億港元。雷蛇今日午間公佈,預期集團於截至今年12月31日止年度將錄得除所得税前經調整溢利(非公認會計原則計量),而去年同期為除所得税前經調整虧損4030萬美元。公告稱,預期錄得扭虧為盈主要由於期內雷蛇的硬件、軟件及服務生態系統的收益增長超出預期。集團的電腦系統業務維持在美國高端遊戲手提電腦市場穩佔第一,保持領先優勢,同時於2020年首3個季度在美國以外的新市場不斷增加市場份額。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.